TrialThe European respiratory journal2025

Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for

Marcus A Mall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.